Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 18Tumor-Agnostic 11Thoracic 5Sarcoma 5Gynecologic 4Breast 4Genitourinary 3CNS 3Lymphoid 2Dermatologic 2Other hematologic neoplasm 1Head & Neck 1

Conditions

Ovarian Neoplasms 25Fallopian Tube Neoplasms 10Uterine Cervical Neoplasms 9Endometrial Neoplasms 6Carcinoma, Ovarian Epithelial 6Urinary Bladder Neoplasms 4Stomach Neoplasms 4Recurrence 4Peritoneal Neoplasms 4Pancreatic Neoplasms 4Neoplasms 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Hepatocellular 2Tumor Virus Infections 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Melanoma 1Lung Neoplasms 1Locally Advanced Cervical Carcinoma 1Locally Advanced Cervical Cancer 1Gallbladder Neoplasms 1Dysgerminoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Cervical Adenocarcinoma 1

Interventions

Paclitaxel 28Carboplatin 28pembrolizumab 25Bevacizumab 14liposomal doxorubicin 12Cisplatin 11Gemcitabine 10Radiotherapy 8Drug Therapy 8Cyclophosphamide 8Blood Specimen Collection 8Topotecan 7Nivolumab 7olaparib 6Doxorubicin 6niraparib 5Therapeutics 5Dexamethasone 5pertuzumab 4pazopanib 4lenvatinib 4fludarabine 4cemiplimab 4atezolizumab 4Trastuzumab 4Surveys and Questionnaires 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Fulvestrant 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasms × Albumin-Bound Paclitaxel × Gynecologic × Clear all
NCT01220154 2025-02-21

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
9 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT02476955 2020-09-30

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Terminated
41 enrolled
BreastGynecologic

Uterine Cervical Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT01219777 2018-02-08

Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
9 enrolled 7 charts
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT00466986 2011-10-12

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

Southeastern Gynecologic Oncology

Phase 2 Completed
40 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡